The use of radiation therapy to treat cancer is well known. Typically, radiation therapy involves directing a beam of high energy proton, photon, ion, or electron radiation (“therapeutic radiation”) into a target, or target volume (e.g., a volume that includes a tumor or lesion).
Before a patient is treated with radiation, a treatment plan specific to that patient is developed. The plan defines various aspects of the therapy using simulations and optimizations based on past experiences. In general, the purpose of the treatment plan is to deliver sufficient radiation to the unhealthy tissue while minimizing exposure of surrounding healthy tissue to the radiation.
The planner's goal is to find a solution that is optimal with respect to multiple clinical goals that may be contradictory in the sense that an improvement toward one goal may have a detrimental effect on reaching another goal. For example, a treatment plan that spares the liver from receiving a dose of radiation may result in the stomach receiving too much radiation. These types of tradeoffs lead to an iterative process in which the planner creates different plans to find the one plan that is best suited to achieving the desired outcome.
A relatively recent radiobiology study has demonstrated the effectiveness of delivering an entire, relatively high therapeutic radiation dose to a target within a single, short period of time. For example, each beam can deliver at least four grays (Gy) in less than one second, and may deliver as much as 20 Gy to 50 Gy or as much as 100 Gy or more in less than one second. This type of treatment is referred to generally herein as FLASH radiation therapy (FLASH RT).
Evidence to date suggests that FLASH RT advantageously spares normal, healthy tissue from damage when that tissue is exposed to a high radiation dose for only a very short period of time. FLASH RT thus introduces important constraints that are not considered in or achieved with conventional radiation treatment planning.
Embodiments according to the present invention provide an improved method of radiation treatment planning, and improved radiation treatment based on such planning, for FLASH radiation therapy (FLASH RT).
In embodiments, information that describes a target inside a patient to be treated with radiation is accessed from computer system memory. An arrangement of spots inside the target is determined. Each of the spots corresponds to a location inside the target where a respective beam of radiation is to be directed during radiation treatment of the patient. A dose rate for each of the beams is determined. The dose rate for each beam is a dose delivered in less than one second to a spot corresponding to that beam. For example, each beam can deliver at least four Grays (GY) in less than one second, and may deliver as much as 20 Gy to 50 Gy or 100 Gy or more in less than one second. A radiation treatment plan, that includes the arrangement of the spots and the dose rate for each of the beams, is stored in computer system memory.
Embodiments according to the invention improve radiation treatment planning and the treatment itself by expanding FLASH RT to a wider variety of treatment modalities and combinations of treatment modalities (e.g., spatially fractionated grid radiation therapy, in addition to intensity modulated radiation therapy such as intensity modulated particle therapy). Treatment plans generated as described herein are superior for sparing normal tissue from radiation in comparison to conventional techniques by reducing, if not minimizing, the magnitude (and the integral in some cases) of the dose to normal tissue (outside the target) by design. Combining the normal tissue sparing of FLASH RT with the tumor-killing effectiveness of spatially fractionated grid radiation therapy enables escalation of radiation dose in most tumors without the associated toxicities of conventional RT, and increase the number of indications treatable with FLASH dose rates. Treatment planning, while still a complex task of finding a balance between competing and related parameters, is simplified relative to conventional planning.
In summary, embodiments according to this disclosure pertain to generating and implementing a treatment plan that is the most effective (relative to other plans) and with the least (or most acceptable) side effects (e.g., a lower dose rate outside of the region being treated). Thus, embodiments according to the invention improve the field of radiation treatment planning specifically and the field of radiation therapy in general. Embodiments according to the invention allow more effective treatment plans to be generated quickly. Also, embodiments according to the invention help improve the functioning of computers because, for example, by reducing the complexity of generating treatment plans, fewer computational resources are needed and consumed, meaning also that computer resources are freed up to perform other tasks.
These and other objects and advantages of embodiments according to the present invention will be recognized by one skilled in the art after having read the following detailed description, which are illustrated in the various drawing figures.
This summary is provided to introduce a selection of concepts that are further described below in the detailed description that follows. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
The accompanying drawings, which are incorporated in and form a part of this specification and in which like numerals depict like elements, illustrate embodiments of the present disclosure and, together with the detailed description, serve to explain the principles of the disclosure.
Reference will now be made in detail to the various embodiments of the present disclosure, examples of which are illustrated in the accompanying drawings. While described in conjunction with these embodiments, it will be understood that they are not intended to limit the disclosure to these embodiments. On the contrary, the disclosure is intended to cover alternatives, modifications and equivalents, which may be included within the spirit and scope of the disclosure as defined by the appended claims. Furthermore, in the following detailed description of the present disclosure, numerous specific details are set forth in order to provide a thorough understanding of the present disclosure. However, it will be understood that the present disclosure may be practiced without these specific details. In other instances, well-known methods, procedures, components, and circuits have not been described in detail so as not to unnecessarily obscure aspects of the present disclosure.
Some portions of the detailed descriptions that follow are presented in terms of procedures, logic blocks, processing, and other symbolic representations of operations on data bits within a computer memory. These descriptions and representations are the means used by those skilled in the data processing arts to most effectively convey the substance of their work to others skilled in the art. In the present application, a procedure, logic block, process, or the like, is conceived to be a self-consistent sequence of steps or instructions leading to a desired result. The steps are those utilizing physical manipulations of physical quantities. Usually, although not necessarily, these quantities take the form of electrical or magnetic signals capable of being stored, transferred, combined, compared, and otherwise manipulated in a computer system. It has proven convenient at times, principally for reasons of common usage, to refer to these signals as transactions, bits, values, elements, symbols, characters, samples, pixels, or the like.
It should be borne in mind, however, that all of these and similar terms are to be associated with the appropriate physical quantities and are merely convenient labels applied to these quantities. Unless specifically stated otherwise as apparent from the following discussions, it is appreciated that throughout the present disclosure, discussions utilizing terms such as “determining,” “accessing,” “generating,” “representing,” “applying,” “indicating,” “storing,” “using,” “adjusting,” “including,” “computing,” or the like, refer to actions and processes (e.g., the flowcharts of
Portions of the detailed description that follows are presented and discussed in terms of methods. Although steps and sequencing thereof are disclosed in figures herein (e.g.,
Embodiments described herein may be discussed in the general context of computer-executable instructions residing on some form of computer-readable storage medium, such as program modules, executed by one or more computers or other devices. By way of example, and not limitation, computer-readable storage media may comprise non-transitory computer storage media and communication media. Generally, program modules include routines, programs, objects, components, data structures, etc., that perform particular tasks or implement particular abstract data types. The functionality of the program modules may be combined or distributed as desired in various embodiments.
Computer storage media includes volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information such as computer-readable instructions, data structures, program modules or other data. Computer storage media includes, but is not limited to, random access memory (RAM), read only memory (ROM), electrically erasable programmable ROM (EEPROM), flash memory or other memory technology, compact disk ROM (CD-ROM), digital versatile disks (DVDs) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium that can be used to store the desired information and that can accessed to retrieve that information.
Communication media can embody computer-executable instructions, data structures, and program modules, and includes any information delivery media. By way of example, and not limitation, communication media includes wired media such as a wired network or direct-wired connection, and wireless media such as acoustic, radio frequency (RF), infrared and other wireless media. Combinations of any of the above can also be included within the scope of computer-readable media.
The system 100 also includes input device(s) 124 such as keyboard, mouse, pen, voice input device, touch input device, etc. Output device(s) 126 such as a display device, speakers, printer, etc., are also included.
In the example of
In the example of
The treatment planning tool set 310 searches through the knowledge base 302 (through the patient records 304) for prior patient records that are similar to the current patient record 312. The statistical models 308 can be used to compare the predicted results for the current patient record 312 to a statistical patient. Using the current patient record 312, a selected treatment type 306, and selected statistical models 308, the tool set 310 generates a radiation treatment plan 322.
More specifically, based on past clinical experience, when a patient presents with a particular diagnosis, stage, age, weight, sex, co-morbidities, etc., there can be a treatment type that is used most often. By selecting the treatment type that the planner has used in the past for similar patients, a first-step treatment type 314 can be chosen. Patient outcomes, which can include normal tissue complication probability as a function of dose rate and patient-specific treatment-type outcomes can be included in the treatment planning process. The medical image processing module 316 provides automatic contouring and automatic segmentation of two-dimensional cross-sectional slides (e.g., from any imaging modality such as, but not limited to, computed tomography (CT), positron emission tomography-CT, magnetic resonance imaging, and ultrasound) to form a three-dimensional (3D) image using the medical images in the current patient record 312. Dose distribution maps and dose rate distribution maps are calculated by the dose and dose rate distribution module 320, which may utilize the optimizer model 150.
In embodiments according to the present invention, the optimizer model 150 uses a dose prediction model to provide, for example, a 3D dose distribution, fluences, and dose rates, and associated dose-volume histograms, dose rate-volume histograms, and irradiation time-volume histograms.
The beam system 404 generates and transports a beam. The beam can be a proton beam, electron beam, photon beam, ion beam, or atom nuclei beam (e.g., carbon, helium, and lithium). In embodiments, depending on the type of beam, the beam system 404 includes components that direct (e.g., bend, steer, or guide) the beam in a direction toward and into the nozzle 406.
In intensity modulated radiation therapy (IMRT) such as intensity modulated particle therapy (IMPT), the intensity of the beam is varied across each treatment region (target) in a patient. In embodiments, the radiation treatment system 400 also includes a beam energy adjuster 405 that can be used to adjust (e.g., reduce or modulate) the energy of the beam entering the nozzle 406. In an embodiment, the beam energy adjuster 405 is part of the nozzle 406. The term “beam energy adjuster” is used herein as a general term for a component or components that affect the energy of the beam, in order to control the range of the beam (e.g., the extent that the beam penetrates into a target), to control the dose delivered by the beam, and/or to control the depth dose curve of the beam, depending on the type of beam. For example, for a proton beam or an ion beam that has a Bragg peak, the beam energy adjuster 405 can control the location of the Bragg peak in a target volume 408 within a patient 410 supported on a patient support device (e.g., a chair or table) in a treatment room (see the discussion of
The target volume 408 may be an organ, a portion of an organ (e.g., a volume or region within the organ), a tumor, diseased tissue, or a patient outline. A target volume may include both unhealthy tissue (e.g., a tumor) and healthy tissue.
The control system 410 of
In the
A beam's eye view of an example of a grid block 460 is shown in
In embodiments according to the invention, the target volume 408 includes an arrangement of spots (e.g., the spots 504 and 506). With reference to
Each beam 412n may be turned on for only a fraction of a second. In embodiments according to the invention, each beam 412n delivers a relatively high dose rate (a relatively high dose in a relatively short period of time) to the target in that fraction of a second. For example, each beam 412n can deliver at least four (4) grays (Gy) in less than one second, and may deliver as much as 20 Gy to 50 Gy or 100 Gy or more in less than one second.
With reference to
As mentioned above, in IMRT (e.g., IMPT), beam intensity is varied across each treatment region (target) in a patient, and in SFGRT, beams can be spatially and temporally fractionated. Depending on the treatment modality, the degrees of freedom available include beam shaping (collimation), beam weighting (spot scanning), beam intensity or energy, beam directions, dose rate, and number and arrangement of spots. Parameters that can affect dose rate also are considered. Such parameters include, but are not limited to, a number of irradiations of the target volume, a duration of each of the irradiations (irradiation times), and a dose deposited in each of the irradiations. The parameters may also include a period of time during which the irradiations are applied (e.g., a number of irradiations are applied over a period of time such as an hour, with each irradiation in the period of time separated from the next by another period of time) and an interval of time between each period of irradiations (e.g., each hour-long period is separated from the next by a day). If the target volume is divided into sub-volumes or voxels, then the values of the parameters can be on a per-sub-volume or per-voxel basis (e.g., a value per sub-volume or voxel). These degrees of freedom lead to an effectively infinite number of potential treatment plans, and therefore consistently and efficiently generating and evaluating high-quality treatment plans is beyond the capability of a human and relies on the use of a computing system, particularly considering the time constraints associated with the use of radiation therapy to treat ailments like cancer, as well as the large number of patients that are undergoing or need to undergo radiation therapy during any given time period.
The discussion to follow refers to beams, target volumes, doses, dose rates, and other elements or values. The discussion below is in the context of modeled elements and calculated values in the treatment planning tool set 310 and the optimizer model 150, unless otherwise noted or made clear in the discussion.
With reference to
In block 704, an arrangement of spots inside the outline of the target volume 408 is determined. Each the spots corresponds to a location inside the target volume 408 where a respective beam 412n or 423n of radiation is to be directed during radiation treatment of the patient.
In block 706, a dose rate for each beam 412n/423n of the beams 412/423 is determined. The dose rate per beam can be the same for all of the beams 412/423, or it can be different across some or all of the beams. That is, in general, each spot in the target does not necessarily have to receive the same dose and dose rate. The dose rate for each beam is a dose delivered in less than one second to a spot corresponding to that beam. For example, each beam can deliver at least 4 Gy in less than one second, and may deliver as much as 20 Gy to 50 Gy or 100 Gy or more in less than one second. In an embodiment, the ratio of the maximum dose rate or the maximum dose inside each spot, to the maximum dose rate or the maximum dose in areas outside the spots is at least 1.5. The areas outside the spots include the region 510 of
In block 708, a radiation treatment plan, that includes the arrangement of the spots and the dose rate for each of the beams, is stored in computer system memory.
With reference now to
In block 804, a number of the spots and an arrangement of the spots in the target volume 408 is determined.
In block 806, a beam energy for each of the beams 412 or beams 423 is determined. The beam energy for each beam of the beams is determined such that each spot receives the minimum prescribed dose rate for that spot.
In block 808, a radiation treatment plan, that includes the number and arrangement of the spots and the beam energy for each of the beams, is stored in computer system memory.
With reference now to
In block 904, information that specifies limits for the radiation treatment plan are accessed. The limits include a minimum limit on dose rate for each spot.
In block 906, the values of the parameters are adjusted until the dose rate for each spot satisfies the minimum limit on dose rate for that spot.
In block 908, a radiation treatment plan, that includes the arrangement of the spots, the beam energies for the beams, and the values of the parameters (from block 906), is stored in computer system memory.
In block 1002 of
In block 1004, beams are directed into spots in a target volume according to the treatment plan as described above in conjunction with
While the operations in
In summary, embodiments according to the invention improve radiation treatment planning and the treatment itself by expanding FLASH RT to a wider variety of treatment modalities and combinations of treatment modalities (e.g., SFGRT, in addition to IMRT and IMPT). Treatment plans generated as described herein are superior for sparing normal tissue from radiation in comparison to conventional techniques by reducing, if not minimizing, the magnitude (and the integral in some cases) of the dose to normal tissue (outside the target) by design. Combining the normal tissue sparing of FLASH RT with the tumor-killing effectiveness of SFGRT enables escalation of radiation dose in most tumors without the associated toxicities of conventional RT, and increase the number of indications treatable with FLASH dose rates. Treatment planning, while still a complex task of finding a balance between competing and related parameters, is simplified relative to conventional planning.
When used with FLASH dose rates, management of patient motion is simplified because the doses are applied in a short period of time (e.g., less than a second).
The techniques described herein may be useful for stereotactic radiosurgery as well as stereotactic body radiotherapy with single or multiple metastases.
Although the subject matter has been described in language specific to structural features and/or methodological acts, it is to be understood that the subject matter defined in the appended claims is not necessarily limited to the specific features or acts described above. Rather, the specific features and acts described above are disclosed as example forms of implementing the claims.
This application is a continuation (divisional) of the application with Ser. No. 16/591,838, entitled “Radiation Treatment Planning for Delivering High Dose Rates to Spots in a Target,” by E Abel et al., filed Oct. 3, 2019, now U.S. Pat. No. 11,291,859 and hereby incorporated by reference in its entirety. This application is related to the application with Ser. No. 17/681,612, entitled “Radiation Treatment Planning for Delivering High Dose Rates to Spots in a Target,” by E Abel et al., filed Feb. 25, 2022.
Number | Name | Date | Kind |
---|---|---|---|
6222544 | Tarr et al. | Apr 2001 | B1 |
6260005 | Yang et al. | Jul 2001 | B1 |
6379380 | Satz | Apr 2002 | B1 |
6411675 | Llacer | Jun 2002 | B1 |
6504899 | Pugachev et al. | Jan 2003 | B2 |
6993112 | Hesse | Jan 2006 | B2 |
7268358 | Ma et al. | Sep 2007 | B2 |
7453983 | Schildkraut et al. | Nov 2008 | B2 |
7515681 | Ebstein | Apr 2009 | B2 |
7560715 | Pedroni | Jul 2009 | B2 |
7590219 | Maurer, Jr. et al. | Sep 2009 | B2 |
7616735 | Maciunas et al. | Nov 2009 | B2 |
7623623 | Raanes et al. | Nov 2009 | B2 |
7778691 | Zhang et al. | Aug 2010 | B2 |
7807982 | Nishiuchi et al. | Oct 2010 | B2 |
7831289 | Riker et al. | Nov 2010 | B2 |
7835492 | Sahadevan | Nov 2010 | B1 |
8401148 | Lu et al. | Mar 2013 | B2 |
8406844 | Ruchala et al. | Mar 2013 | B2 |
8559596 | Thomson et al. | Oct 2013 | B2 |
8600003 | Zhou et al. | Dec 2013 | B2 |
8613694 | Walsh | Dec 2013 | B2 |
8636636 | Shukla et al. | Jan 2014 | B2 |
8644571 | Schulte et al. | Feb 2014 | B1 |
8716663 | Brusasco et al. | May 2014 | B2 |
8847179 | Fujitaka et al. | Sep 2014 | B2 |
8948341 | Beckman | Feb 2015 | B2 |
8986186 | Zhang et al. | Mar 2015 | B2 |
8995608 | Zhou et al. | Mar 2015 | B2 |
9018603 | Loo et al. | Apr 2015 | B2 |
9033859 | Fieres et al. | May 2015 | B2 |
9149656 | Tanabe | Oct 2015 | B2 |
9155908 | Meltsner et al. | Oct 2015 | B2 |
9233260 | Slatkin et al. | Jan 2016 | B2 |
9283406 | Prieels | Mar 2016 | B2 |
9308391 | Liu et al. | Apr 2016 | B2 |
9333374 | Iwata | May 2016 | B2 |
9517358 | Velthuis et al. | Dec 2016 | B2 |
9545444 | Strober et al. | Jan 2017 | B2 |
9636381 | Basile | May 2017 | B2 |
9636525 | Sahadevan | May 2017 | B1 |
9649298 | Djonov et al. | May 2017 | B2 |
9656098 | Goer | May 2017 | B2 |
9694204 | Hårdemark | Jul 2017 | B2 |
9776017 | Flynn et al. | Oct 2017 | B2 |
9786093 | Svensson | Oct 2017 | B2 |
9795806 | Matsuzaki et al. | Oct 2017 | B2 |
9884206 | Schulte et al. | Feb 2018 | B2 |
9931522 | Bharadwaj et al. | Apr 2018 | B2 |
9962562 | Fahrig et al. | May 2018 | B2 |
9974977 | Lachaine et al. | May 2018 | B2 |
9987502 | Gattiker et al. | Jun 2018 | B1 |
10007961 | Grudzinski et al. | Jun 2018 | B2 |
10071264 | Liger | Sep 2018 | B2 |
10092774 | Vanderstraten et al. | Oct 2018 | B1 |
10183179 | Smith et al. | Jan 2019 | B1 |
10206871 | Lin et al. | Feb 2019 | B2 |
10232193 | Iseki | Mar 2019 | B2 |
10258810 | Zwart et al. | Apr 2019 | B2 |
10279196 | West et al. | May 2019 | B2 |
10307614 | Schnarr | Jun 2019 | B2 |
10315047 | Glimelius et al. | Jun 2019 | B2 |
10413755 | Sahadevan | Sep 2019 | B1 |
10525285 | Friedman | Jan 2020 | B1 |
10549117 | Vanderstraten et al. | Feb 2020 | B2 |
10603514 | Grittani et al. | Mar 2020 | B2 |
10609806 | Roecken et al. | Mar 2020 | B2 |
10661100 | Shen | May 2020 | B2 |
10702716 | Heese | Jul 2020 | B2 |
20070287878 | Fantini et al. | Dec 2007 | A1 |
20100178245 | Arnsdorf et al. | Jul 2010 | A1 |
20110006224 | Maltz et al. | Jan 2011 | A1 |
20110091015 | Yu et al. | Apr 2011 | A1 |
20120157746 | Meltsner et al. | Jun 2012 | A1 |
20120171745 | Itoh | Jul 2012 | A1 |
20130131428 | Jiang | May 2013 | A1 |
20130231516 | Loo et al. | Sep 2013 | A1 |
20130281999 | Adler | Oct 2013 | A1 |
20140275706 | Dean et al. | Sep 2014 | A1 |
20150011817 | Feng | Jan 2015 | A1 |
20150202464 | Brand et al. | Jul 2015 | A1 |
20150306423 | Bharat et al. | Oct 2015 | A1 |
20160279444 | Schlosser | Sep 2016 | A1 |
20160310764 | Bharadwaj et al. | Oct 2016 | A1 |
20170165502 | Claereboudt et al. | Jun 2017 | A1 |
20170189721 | Sumanaweera et al. | Jul 2017 | A1 |
20170203129 | Dessy | Jul 2017 | A1 |
20170281973 | Allen et al. | Oct 2017 | A1 |
20180021594 | Papp et al. | Jan 2018 | A1 |
20180043183 | Sheng et al. | Feb 2018 | A1 |
20180056090 | Jordan et al. | Mar 2018 | A1 |
20180099154 | Prieels | Apr 2018 | A1 |
20180099155 | Prieels et al. | Apr 2018 | A1 |
20180099159 | Forton et al. | Apr 2018 | A1 |
20180154183 | Sahadevan | Jun 2018 | A1 |
20180197303 | Jordan et al. | Jul 2018 | A1 |
20180236268 | Zwart et al. | Aug 2018 | A1 |
20190022407 | Abel et al. | Jan 2019 | A1 |
20190022409 | Vanderstraten et al. | Jan 2019 | A1 |
20190022422 | Trail et al. | Jan 2019 | A1 |
20190054315 | Isola et al. | Feb 2019 | A1 |
20190070435 | Joe Anto et al. | Mar 2019 | A1 |
20190168027 | Smith et al. | Jun 2019 | A1 |
20190255361 | Mansfield | Aug 2019 | A1 |
20190299027 | Fujii et al. | Oct 2019 | A1 |
20190299029 | Inoue | Oct 2019 | A1 |
20190351259 | Lee et al. | Nov 2019 | A1 |
20200001118 | Snider, III et al. | Jan 2020 | A1 |
20200022248 | Yi et al. | Jan 2020 | A1 |
20200030633 | Van Heteren et al. | Jan 2020 | A1 |
20200035438 | Star-Lack et al. | Jan 2020 | A1 |
20200069818 | Jaskula-Ranga et al. | Mar 2020 | A1 |
20200164224 | Vanderstraten et al. | May 2020 | A1 |
20200178890 | Otto | Jun 2020 | A1 |
20200197730 | Safavi-Naeini et al. | Jun 2020 | A1 |
20200254279 | Ohishi | Aug 2020 | A1 |
20200269068 | Abel et al. | Aug 2020 | A1 |
20200276456 | Swerdloff | Sep 2020 | A1 |
20200282232 | Varian | Sep 2020 | A1 |
20200282234 | Folkerts et al. | Sep 2020 | A1 |
20200298023 | Cooley, III et al. | Sep 2020 | A1 |
20210252307 | Kontaxis | Aug 2021 | A1 |
Number | Date | Country |
---|---|---|
104001270 | Aug 2014 | CN |
106730407 | May 2017 | CN |
107362464 | Nov 2017 | CN |
109966662 | Jul 2019 | CN |
111481840 | Aug 2020 | CN |
111481841 | Aug 2020 | CN |
010207 | Jun 2008 | EA |
0979656 | Feb 2000 | EP |
3178522 | Jun 2017 | EP |
3338858 | Jun 2018 | EP |
3384961 | Oct 2018 | EP |
3421087 | Jan 2019 | EP |
3453427 | Mar 2019 | EP |
3586920 | Jan 2020 | EP |
2617283 | Jun 1997 | JP |
2019097969 | Jun 2019 | JP |
WO-2007017177 | Feb 2007 | WO |
WO-2010018476 | Feb 2010 | WO |
WO-2013081218 | Jun 2013 | WO |
WO-2013133936 | Sep 2013 | WO |
WO-2014139493 | Sep 2014 | WO |
WO-2015038832 | Mar 2015 | WO |
WO-2015102680 | Jul 2015 | WO |
WO-2016122957 | Aug 2016 | WO |
WO-2017156316 | Sep 2017 | WO |
WO-2017174643 | Oct 2017 | WO |
WO-2018137772 | Aug 2018 | WO |
WO-2018152302 | Aug 2018 | WO |
WO-2019097250 | May 2019 | WO |
WO-2019103983 | May 2019 | WO |
WO-2019164835 | Aug 2019 | WO |
WO-2019166702 | Sep 2019 | WO |
WO-2019185378 | Oct 2019 | WO |
WO-2019222436 | Nov 2019 | WO |
WO-2020018904 | Jan 2020 | WO |
WO-2020064832 | Apr 2020 | WO |
WO-2020107121 | Jun 2020 | WO |
WO-2020159360 | Aug 2020 | WO |
WO-2020181118 | Sep 2020 | WO |
WO-2020185544 | Sep 2020 | WO |
Entry |
---|
M. McManus et al., “The challenge of ionisation chamber dosimetry in ultra-short pulsed high dose-rate Very High Energy Electron beams,” Sci Rep 10, 9089 (2020), published Jun. 3, 2020,; hllps://doi.org/10.1038/s41598-020-65819-y. |
Ibrahim Oraiqat et al., “An Ionizing Radiation Acoustic Imaging {iRAI) Technique for Real-Time Dosimetric Measurements for FLASH Radiotherapy,” Medical Physics, vol. 47, Issue10, Oct. 2020, pp. 5090-5101, First published: Jun. 27, 2020,; hllps://doi.org/10.1002/mp. 14358. |
K. Petersson et al., “Dosimetry of ultra high dose rate irradiation for studies on the biological effect induced in normal brain and Gbm,” ICTR-PHE 2016, page S84, Feb. 2016, https://publisher-connector.core.ac.uk/resourcesync/data/elsevier/pdf/14c/ aHROcDovL2FwaS51bHNIdmllci5jb20vY29udGVudC9hcnRpY2xIL3BpaS9zMDE2NzgxNDAx NjMwMTcyNA ==.pdf. |
Susanne Auer et al., “Survival of tumor cells after proton irradiation with ultra-high dose rates,” Radiation Oncology 2011, 6:139, Published Oct. 18, 2011,; DOI: hllps://doi.org/10.1186/1748-717X-6-139. |
Cynthia E. Keen, “Clinical linear accelerator delivers FLASH radiotherapy,” Physics World, Apr. 23, 2019, IOP Publishing Lid,; https://physicsworld.com/a/clinical-linear-accelerator-delivers-flash-radiotherapy/. |
Fan et al., “Emission guided radiation therapy for lung and prostate cancers: A feasibility study on a digital patient,” Med Phys. Nov. 2012; 39(11): 7140-7152. Published online Nov. 5, 2012. < https://www.ncbi.nlm.nih.gov/pmc/arlicles/PMC3505203/> doi: 10.1118/1.4761951. |
Favaudon et al., “Ultrahigh dose-rate, “flash” irradiation minimizes the side-effects of radiotherapy,” Cancer/ Radiotherapy, vol. 19, Issues 6---7 , Oct. 2015 , pp. 526-531, Available online Aug. 12, 2015, https://doi.org/10.1016/j.canrad.2015.04.006. |
O. Zlobinskaya et al., “The Effects of Ultra-High Dose Rate Proton Irradiation on Grow1h Delay in the Treatment of Human Tumor Xenografts in Nude Mice,” Radiation Research, 181(2):177-183. Published Feb. 13, 2014,; DOI: http://dx.doi.org/10.1667/RR13464.1. |
Bjorn Zackrisson, “Biological Effects Of High Energy Radiation And Ultra High Dose Rates,” UMEA University Medical Dissertations, New series No. 315-ISSN 0346-6612, From the Department of Oncology, University of Umea, Umea, Sweden, ISBN 91-7174-614-5, Printed in Sweden by the Printing Office of Umea University, Umea, 1991. |
P. Montay-Gruel et al., “Irradiation in a flash: Unique sparing of memory in mice after whole brain irradiation with; dlose rates above 100 Gy/s,” Radiotherapy and Oncology, vol. 124, Issue 3, Sep. 2017, pp. 365-369,; Available online May 22, 2017,; doi: 10.1016/j.radonc.2017.05.003. |
BW Loo et al., “Delivery of Ultra-Rapid Flash Radiation Therapy and Demonstration of Normal Tissue Sparing After Abdominal Irradiation of Mice,” International Journal of Radiation Oncology, Biology, Physics,; vol. 98, Issue 2, p. E16, Supplement: S Meeting Abstract: P003, Published: Jun. 1, 2017,; DOI: hllps://doi.org/10.1016/j.ijrobp.2017.02.101. |
Bhanu Prasad Venkatesulu et al., “Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome,” Sci Rep 9, 17180 (2019), Published Nov. 20, 2019, DOI: https://doi.org/10.1038/s41598-019-53562-y. |
P. Montay-Gruel et al., “Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species,” PNAS May 28, 2019, vol. 116, No. 22, pp. 10943-10951; first published May 16, 2019, https://doi.org/10.1073/pnas.1901777116. |
Peter G. Maxim et al., “FLASH radiotherapy: Newsflash or flash in the pan?”, Medical Physics, 46 (10), Oct. 2019, pp. 4287-4290, American Association of Physicists in Medicine, First published: Jun. 27, 2019, https://doi.org/10.1002/mp. 13685. |
Andrei Pugachev et al., “Pseudo beam's-eye-view as applied to beam orientation selection in intensity-modulated radiation therapy,” Int. J. Radiation Oncology Biol. Phys., vol. 51, Issue 5, P1361-1370, Dec. 1, 2001, DOI: https://doi.org/10.1016/S0360-3016(01)01736-9. |
Xiaodong Zhang et al., “Intensity-Modulated Proton Therapy Reduces the Dose to Normal Tissue Compared With; Inlensity-Modulaled Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small-Cell Lung Cancer: A Virtual Clinical Study,” Int. J_ RadiationOncology Biol. Phys., vol. 77, No. 2, pp. 357-366, 2010, Available online Aug. 5, 2009,; DOI: https://doi.ora/10.1016/i.iirobo.2009.04.028. |
A.J. Lomax et al, “Intensity modulated proton therapy: A clinical example,” Medical Physics, vol. 28, Issue 3, Mar. 2001, pp. 317-324, First published: Mar. 9, 2001, https://doi.org/10.1118/1.1350587. |
Lamberto Widesott et al., “Intensity-Modulated Proton Therapy Versus Helical Tomolherapy in Nasopharynx; Cancer: Planning Comparison and NTCP Evaluation,” Int. J_Radiation Oncology Biol. Phys., vol. 72, No. 2, pp. 589-596, Oct. 1, 2008, Available online Sep. 13, 2008,; DOI: https://doi.org/10.1016/j.ijrobp.2008.05.065. |
Andrei Pugachev et al., “Role of beam orientation optimization in intensity-modulated radiation therapy,” Int. J. Radiation Oncology Biol. Phys., vol. 50, No. 2, pp. 551-560, Jun. 1, 2001, Available online May 10, 2001, DOI: https://doi.org/10.1016/S0360-3016(01)01502-4. |
Damien C. Weber et al., “Radiation therapy planning with photons and protons for early and advanced breast cancer: an overview,” Radial Oncol. 2006; 1:22. Published online Jul. 2, 20060,; doi: 10.1186/1748-717X-1-22. |
RaySearch Laboratories, “Leading the way in cancer treatment, Annual Report 2013,” RaySearch Laboratories (publ), Stockholm, Sweden, 94 pages, Apr. 2014, <https://www.raysearchlabs.com/siteassels/about-overview/media-cenler/wp-re-ev-n-pdfs/brochures/raysearch-ar-2013> eng.pdf. |
Redrik Carlsson, “Utilizing Problem Structure in Optimization of Radiation Therapy,” KTH Engineering Sciences, Doctoral Thesis, Stockholm, Sweden, Apr. 2008, Optimization and Systems Theory, Deparlmenl of Mathematics, Royal Institute ofTechnology, Stockholm, Sweden, ISSN 1401-2294, <https://www.raysearchlabs.com/globalassels/about-overview/media-cenler/wp-re-ev-n-pdfs/publicalions/lhesis-> fredrik light.pdf. |
Chang-Ming Charlie Ma, “Physics and Dosimetric Principles of SRS and SBRT,” Mathews J Cancer Sci. 4(2): 22, 2019, published: Dec. 11, 2019, ISSN: 2474-6797, DOI: https://doi.org/10.30654/MJCS.10022. |
Alterego-Admin, “Conventional Radiation Therapy May Not Protect Healthy Brain Cells,”; Intemational Neuropsychiatric Association—INA, Oct. 10, 2019, https://inawebsite.org/conventional-radiation-therapy-may-not-protect-healthy-brain-cells/. |
Aafke Christine Kraan, “Range verification methods in particle therapy: underlying physics and Monie Carlo modeling,” Frontiers in Oncology, Jul. 7, 2015, vol. 5, Article 150, 27 pages, doi: 10.3389/fonc.2015.00150. |
Wayne D. Newhauser et al., “The physics of proton therapy,” Physics in Medicine & Biology, Mar. 24, 2015, 60 R155-R209, Institute of Physics and Engineering in Medicine, IOP Publishing, doi: 10. 1088/003-9155/60/8/R155. |
Se McGowan et al., “Treatment planning optimisation in proton therapy,” Br J Radiol, 2013, 86, 20120288, The British Institute of Radiology, 12 pages, DOI: 10.1259.bjr.20120288. |
Steven Van De Water et al., “Towards FLASH proton therapy: the impact of treatment planning and machine characlerislics on achievable dose rates,” Acta Oncologica, Jun. 26, 2019, vol. 58, No. 10, pp. 1462-1469, Taylo & Francis Group, DOI: 10.1080/0284186X.2019.1627416. |
J-Groen, “FLASH optimisation in clinical IMPT treatment planning,” MSc Thesis, Jul. 1, 2020, Erasmus University Medical Center, department of radiotherapy, Delft University of Technology, 72 pages. |
Muhammad Ramish Ashraf et al., “Dosimetry for FLASH Radiotherapy: A Review of Tools and the Role of Radioluminescence and Cherenkov Emission,” Frontiers in Oncology, Aug. 21, 2020, vol. 8, Article 328, 20 pages, doi: 10.3389/fphy.2020.00328. |
Emil Schuler et al., “Experimental Platform for Ultra-high Dose Rate FLASH Irradiation of Small Animals Using a; clinical Linear Accelerator,” International Journal of Radiation Oncology, Biology, Physics, vol. 97, No. 1, Sep. 2016, pp. 195-203. |
Elette Engels et al., “Toward personalized synchrotron microbeam radiation therapy,” Scientific Reports, 10:8833, Jun. 1, 2020, 13 pages, DOI: https://doi.org/10.1038/s41598-020-65729-z. |
P-H Mackeprang et al., “Assessing dose rate distributions in VMAT plans” (Accepted Version), Accepled Version: hllps://boris.unibe.ch/92814/8/dose_rate_project_revised_submil.pdf; Published Version: 2016, Physics in medicine and biology, 61(8), pp. 3208-3221. Institute of Physics Publishing IOP,; published Mar. 29, 2016, https://boris.unibe.ch/92814/. |
Xiaoying Liang et al., “Using Robust Optimization for Skin Flashing in Intensity Modulated Radiation Therapy for Breast Cancer Treatment: A Feasibility Study,” Practical Radiation Oncology, vol. 10, Issue 1, pp. 59-69, Published by Elsevier Inc., Oct. 15, 2019. |
Alexei Trofimov et al., “Optimization of Beam Parameters and Treatment Planning for Intensity Modulated Proton Therapy,” Technology in Cancer Research & Treatment, vol. 2, No. 5, Oct. 2003, pp. 437-444, Adenine Press. |
Vladimir Anferov, “Scan pattern optimization for uniform proton beam scanning,” Medical Physics, vol. 36, Issue 8, Aug. 2009, pp. 3560-3567, First published: Jul. 2, 2009. |
Ryosuke Kohno et al., “Development of Continuous Line Scanning System Prototype for Proton Beam Therapy,” International Journal of Particle Therapy, Jul. 11, 2017, vol. 3, Issue 4, pp. 429-438, DOI: 10.14338/IJPT-16-00017.1. |
Wenbo Gu et al., “Integrated Beam Orientation and Scanning-Spot Optimization in Intensity Modulated Proton; Therapy for Brain and Unilateral Head and Neck Tumors,” Med Phys. Author manuscript; available in PMC Apr. 1, 2019 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904040/; Published in final edited form as: Med Phys. Apr. 2018; 45(4): 1338--1350. Published online Mar. 1, 2018.; doi: 10.1002/mo.12788 Acceoted manuscriot online: Feb. 2, 2018. |
Paul Morel et al., “Spot weight adaptation for moving target in spot scanning proton therapy,” Frontiers in Oncology, May 28, 2015, vol. 5, Article 119, 7 pages, doi: 10.3389/fonc.2015.00119. |
Simeon Nill et al., “Inverse planning of intensity modulated proton therapy,” Zeitschrift fur Medizinische Physik, vol. 14, Issue 1, 2004, pp. 35-40, hllps://doi.org/10.1078/0939-3889-00198. |
M Kramer et al., “Treatment planning for heavy-ion radiotherapy: physical beam model and dose optimization,” Physics in Medicine & Biology, 2000, vol. 45, No. 11, pp. 3299-3317, doi: 10.1088/0031-9155/45/11/313. |
Harald Paganetti, “Proton Beam Therapy,” Jan. 2017, Physics World Discovery, IOP Publishing Ltd, Bristol, UK, 34 pages, DOI: 10.1088/978-0-7503-1370-4. |
Shinichi Shimizu et al., “A Proton Beam Therapy System Dedicated to Spot-Scanning Increases Accuracy with Moving Tumors by Real-Time Imaging and Gating and Reduces Equipment Size,” PLoS One, Apr. 18, 2014, vol. 9, Issue 4, e94971, https://doi.org/10.1371/journal.pone.0094971. |
Heng Li et al., “Reducing Dose Uncertainty for Spot-Scanning Proton Beam Therapy of Moving Tumors by Optimizing the Spot Delivery Sequence,” International Journal of Radiation Oncology, Biology, Physics, vol. 93, Issue 3, Nov. 1, 2015, pp. 547-556, available online Jun. 18, 2015, https://doi.org/10.1016/j.ijrobp.2015.06.019. |
Ion Beam Applications SA, “Netherlands Proton Therapy Center Delivers First Clinical Flash Irradiation,” Imaging Technology News, May 2, 2019, Wainscot Media, https://www.itnonline.com/content/netherlands-proton-therapy-center-delivers-first-clinical-flash-irradiation. |
R. M. De Kruijff, “FLASH radiotherapy: ultra-high dose rates to spare healthy tissue,” International Journal of Radiation Biology, 2020, vol. 96, No. 4, pp. 419-423, published online: Dec. 19, 2019, https://doi.org/10.1080/09553002.2020.1704912. |
Mevion Medical Systems, “Focus On The Future: Flash Therapy,” Press Releases, Sep. 16, 2019<https://www.mevion.com/newsroom/press-releases/focus-future-flash-therapy>. |
Joseph D. Wilson et al., “Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?”, Frontiers in Oncology, Jan. 17, 2020, vol. 9, Article 1563, 12 pages, doi: 10.3389/fonc.2019.01563. |
David P. Gierga, “Is Flash Radiotherapy coming?”, International Organization for Medical Physics, 2020, <https://www.iomp.org/iomp-news2-flash-radiolherapy/>. |
Abdullah Muhammad Zakaria et al., “Ultra-High Dose-Rate, Pulsed (FLASH) Radiotherapy with Carbon Ions: Generation of Early, Transient, Highly Oxygenated Conditions in the Tumor Environment,” Radiation Research, Dec. 1, 2020, vol. 194, Issue 6, pp. 587-593, Radiation Research Society, Published: Aug. 27, 2020,; doi: hllps://doi.org/10.1667/RADE-19-00015.1. |
Yusuke Demizu et al., “Carbon Ion Therapy for Early-Stage Non-Small-Cell Lung Cancer,” BioMed Research International, vol. 2014, Article ID 727962, 9 pages, Hindawi Publishing Corporation, published: Sep. 11, 2014, https://doi.org/10.1155/2014/727962. |
Ivana Dokic et al., “Next generation multi-scale biophysical characterization of high precision cancer particle radiolherapy using clinical proton, helium-, carbon- and oxygen ion beams,” Oncolarget, Aug. 30, 2016, vol. 7, No. 35, p. 56676-56689, published online: Aug. 1, 2016,; doi: 10.18632/oncolargel.10996. |
Aetna Inc., “Proton Beam, Neutron Beam, and Carbon Ion Radiotherapy,” 2020, No. 0270, http://www.aetna.com/cpb/medical/dala/200_299/0270.hlml. |
Nicholas W. Colangelo et al., “The Importance and Clinical Implications of FLASH Ultra-High Dose-Rate Sludie! for Proton and Heavy Ion Radiotherapy,” Radial Res. Author manuscript; available in PMC Jan. 1, 2021. < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949397/> Published in final edited form as: Radial Res. Jan. 2020; 193(1): 1--4. Published online Oct. 2, 20198. doi: 10.1667/RR15537.1. |
Vincent Favaudon et al., “Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice,” Science Translational Medicine, Jul. 16, 2014, vol. 6, Issue 245, 245ra93, American Association for the Advancement of Science, DOI: 10.1126/scitranslmed.3008973. |
FlashRad: Ultra-high dose-rate FLASH radiotherapy to minimize the complications of radiotherapy, 2014, https://siric.curie.fr/sites/default/files/aloms/files/flashrad.pdf. |
Tami Freeman, “Flash radiotherapy: from preclinical promise to the first human treatment,” Physics World, Aug. 6, 2019, IOP Publishing Lid,; https://physicsworld.com/a/llash-radiotherapy-from-preclinical-promise-to-the-first-human-treatmenl/. |
Intraop Medical, Inc., “IntraOp and Lausanne University Hospital Announce Collaboration in FLASH adiotherapy,” Jun. 18, 2020,; https://intraop.com/news-events/lausanne-universily-flash-radiotherapy-collaboration/. |
M.-C. Vozenin et al., “Biological Benefits of Ultra-high Dose Rate FLASH Radiotherapy: Sleeping Beauty Awoken,” Clin Oncol {R Coll Radiol). Author manuscript; available in PMC Nov. 12, 2019. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850216/> Published in final edited form as: Clin Oncol {R Coll Radiol). Jul. 2019; 31(7): 40 --415. Published online 2019 Aor 19. doi: 10.1016/i.clon.2019.04.001. |
Efstathios Kamperis et al., “A Flash back to radiotherapy's past and then fast forward to the future,” J Cancer Prev Curr Res. 2019;10(6): 142-144. published Nov. 13, 2019, DOI: 10.15406/jcpcr.2019.10.00407. |
P. Symonds et al., “FLASH Radiotherapy: The Next Technological Advance in Radiation Therapy?”, Clinical; Oncology, vol. 31, Issue 7, pp. 405-406, Jul. 1, 2019, The Royal College of Radiologists, Published by Elsevier Lid., DOI: https://doi.org/10.1016/j.clon.2019.05.011. |
Swati Girdhani et al., “Abstract LB-280: Flash: A novel paradigm changing tumor irradiation platform that enhances therapeutic ratio by reducing normal tissue toxicity and activating immune pathways,” Proceedings: AACR Annual Meeting 2019; Mar. 29-Apr. 3, 2019; Atlanta, GA, published Jul. 2019, vol. 79, Issue 13 Supplement, pp. B-280, American Association for Cancer Research,; DOI: https://doi.org/10.1158/1538-7445.AM2019-LB-280. |
Bazalova-Carter et al., “On the capabilities of conventional x-ray tubes to deliver ultra-high (FLASH) dose rates,” Med. Phys. Dec. 2019; 46 (12):5690-5695, published Oct. 23, 2019, American Association of Physicists in Medicine doi: 10.1002/mp.13858. Epub Oct. 23, 2019. PMID: 31600830. |
Manuela Buonanno et al., “Biological effects in normal cells exposed to FLASH dose rate protons,” Radiother Oncol. Author manuscript; available in PMC Oct. 1, 2020. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728238/> Published in final edited form as: Radiother Oncol. Oct. 2019; 139: 51-55. Published online Mar. 5, 2019. doi: 10.1016/i.radonc.2019.02.009. |
N. Rama et al., “Improved Tumor Control Through T-cell Infiltration Modulated by Ultra-High Dose Rate Proton FLASH Using a Clinical Pencil Beam Scanning Proton System,” International Journal of Radiation Oncology, Biology, Physics, vol. 105, Issue 1, Supplement, S164-S165, Sep. 1, 2019, Mini Oral Sessions, DOI: https://doi.org/10.1016/j.ijrobp.2019.06.187. |
Inserm Press Office, “Radiotherapy ‘flashes’ to reduce side effects,” Press Release, Jul. 16, 2014, https://presse.inserm.fr/en/radiotherapy-flashes-to-reduce-side-effects/13394/. |
Eric S. Diffenderfer et al., “Design, Implementation, and in Vivo Validation of a Novel Proton FLASH Radiation Therapy System,” International Journal of Radiation Oncology, Biology, Physics, vol. 106, Issue 2, Feb. 1, 2020, pp. 440-448, Available online Jan. 9, 2020, Published by Elsevier Inc., DOI: https://doi.org/10.1016/j.ijrobp.2019.10.049. |
Valerie Devillaine, “Radiotherapy and Radiation Biology,” Institut Curie, Apr. 21, 2017, https://institut-curie.org/page/radiotherapy-and-ratiaion-biology. |
Maging Technology News, “ProNova and medPhoton to Offer Next Generation Beam Delivery, Advanced Imaging for Proton Therapy,” Oct. 6, 2014, Wainscot Media, Link: https://www.itnonline.com/content/pronova-and-medphoton--offer-next-generation-beam-delivery-advanced-< http://www.itnonline.com/content/pronova-and-medphoton--offer-next-generation-beam-delivery-advanced-> imaging-proton-therapy. |
Oncolink Team, “Radiation Therapy: Which type is right for me?”, OncoLink Penn Medicine, last reviewed Mar. 3, 2020, Trustees of the University of Pennsylvania, https://www.oncolink.org/cancer-treatment/radiation/introduction-to-radiation-therapy/radiation-therapy-which-type-is-right-for-me. |
Marco Durante et al., “Faster and safer? FLASH ultra-high dose rate in radiotherapy,” Br J Radiol 2018; 91(1082): 20170628, British Institute of Radiology, Published Online: Dec. 15, 2017, https://doi.org/10.1259/bjr-20170628. |
Uohn R. Fischer, “PMB launches FLASH radiotherapy system for use in clinical trials,” HealthCare Business News,Jun. 29, 2020, DOTmed.com, Inc., nttps://www.dotmed.com/news/story/51662 <http://www.dotmed.com/news/story/51662. |
Marie-Catherine Vozenin et al., “The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients,” Clinical Cancer Research, Author Manuscript Published OnlineFirst Jun. 6, 2018, https://clincancerres.aacrjournals.org/content/clincanres/early/2018/06/06/1078-0432 .CCR-17-3375full.pdf. |
Number | Date | Country | |
---|---|---|---|
20220176158 A1 | Jun 2022 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16591838 | Oct 2019 | US |
Child | 17681565 | US |